retatrutide phase 2 nejm 2023 obesity trial jastreboff Just Broke Every Record Retatrutide Phase 2 NEJM Trial:

To investigate whether the metabolic effects of mGIPR-Ab/GLP-1 are similar in female mice, we treated female HFD-fed Glp1r fl/fl control and Glp1r Wnt1/ mice with IP injection of either vehicle or mGIPR-Ab/P1 every 6 days for 18 days

Nausea is one of the most commonly reported side effects of GLP-1 medications (12)

It is by no means an overstatement to say that this approach was wildly successful in unlocking GLP-1s therapeutic potential

Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies

The initial effect of this increased insulin release is to help reduce how much glucose remains circulating in your bloodstream